News & Events:HZNP

Susquehanna upgraded the previous rating for Lattice Semiconductor Corp from Neutral to Positive. According to Barclays, the prior rating for Otis Worldwide Corp was changed from Equal-Weight to Overweight. B of A Securities upgraded the previous rating for Northwest Natural Holding Co from Underperform to Neutral.

-- Oral presentation on KRYSTEXXA® plus methotrexate to be held June 2, 2022 at 11:35 a.m. CEST-- -- Additional data presentations provide new insights on psychosocial and comorbidity impact of gout to help inform evolving treatment strategies -- DUBLIN---- Horizon Therapeutics plc (HZNP) today announced a series of data presentations during The EULAR 2022 European Congress of Rheumatology, June 1 – 4...

  See all analyst ratings upgrades.   See all analyst ratings downgrades.   See all analyst ratings initiations.

Horizon Therapeutics has observed the following analyst ratings within the last quarter: These 4 analysts have an average price target of $127.5 versus the current price of Horizon Therapeutics at $90.35, implying upside. Below is a summary of how these 4 analysts rated Horizon Therapeutics over the past 3 months.

According to Benzinga Pro, during Q1, Horizon Therapeutics earned $204.26 million, a 17.95% increase from the preceding quarter. Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business.

Horizon Therapeutics plc enrolled first patient in a Phase 2, open-label, proof-of-concept trial of its drug candidate Daxdilimab to treat people with moderate-to-severe alopecia areata. The company is planning to enrol approximately 30 participants in this study. The primary endpoint in this phase of the study is the percent change from baseline in Severity of Alopecia Tool score at Week 24.

Horizon Therapeutics plc (HZNP) today announced the first patient has enrolled in a Phase 2, open-label, proof-of-concept trial to evaluate its development-stage medicine daxdilimab, a potentially first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7, to treat people with moderate-to-severe alopecia areata.

Among patient groups familiar with Horizon, the company ranked first in patient group relationships, integrity, services beyond the pill and patient centricity Horizon Therapeutics plc (HZNP) today announced that it ranked second in overall corporate reputation among U.S. patient groups who were familiar with the company and third among groups who reported working with the company.

Horizon Therapeutics plc (HZNP) today announced that Dara Mann, vice president, marketing, ophthalmology, has been named a 2022 Healthcare Businesswomen’s Association Rising Star. The HBA is the leading nonprofit global organization committed to furthering the advancement and impact of women in health care.

-- Nationwide campaign spotlights mental health impact of living with TED -- For Mental Health Awareness Month and Healthy Vision Month in May, Horizon Therapeutics plc (HZNP) is partnering with mental health expert and New York Times best-selling author, Lori Gottlieb, to highlight the emotional burden of living with TED – a serious, progressive, and potentially vision-threatening rare autoimmune con...

Horizon Therapeutics PLC (HZNP): * HORIZON THERAPEUTICS AND CHICAGO SKY ANNOUNCE MULTI-YEAR PARTNERSHIP. * Horizon Therapeutics PLC (HZNP) - PARTNERSHIP MAKES HORIZON OFFICIAL AND EXCLUSIVE BIOTECH PARTNER OF CHICAGO SKY AND INCLUDES COMMUNITY PROGRAMMING Source text for Eikon: Further company coverage:

- Partnership Makes Horizon the Official and Exclusive Biotech Partner of the Chicago Sky and Includes Community Programming - Horizon Therapeutics (HZNP) and the Chicago Sky today announced a multi-year partnership, which includes robust community programming as well as marketing and branding assets.

  Horizon Therapeutics reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Horizon Therapeutics beat estimated earnings by 11.67%, reporting an EPS of $1.34 versus an estimate of $1.2. Revenue was up $542.84 million from the same period last year.

First-Quarter 2022 Results: -- Net Sales of $885.2 Million -- -- GAAP Net Income of $204.3 Million; Adjusted EBITDA of $371.2 Million -- -- TEPEZZA® Net Sales of $501.5 Million -- -- KRYSTEXXA® Net Sales of $140.7 Million -- -- Cash Position of $1.64 Billion as of March 31, 2022 -- Full-Year 2022 Guidance: -- Maintaining Full-Year 2022 Net Sales Guidance of $3.9 Billion to $4.0 Billion, Represe...

  ** Seres Therapeutics is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million. ** Obsidian Energy is projected to report quarterly earnings at $0.41 per share on revenue of $156.00 million. ** International Seaways is estimated to report quarterly loss at $0.31 per share on revenue of $96.75 million.

Detailed results to be presented at upcoming medical congress Horizon Therapeutics plc (HZNP) today announced that its Phase 2, randomized, double-blinded, placebo-controlled trial of dazodalibep in rheumatoid arthritis met the primary endpoint.

Horizon Therapeutics plc (HZNP) today announced the launch of the #RAREis Global Advocate Grant, a new program designed to support the rare disease community by providing financial assistance to U.S. and global patient advocacy groups working to advance, educate and address the needs of the community.

Horizon Therapeutics' Inebilizumab Scores European Approval For Spinal Cord Inflammation

Horizon Therapeutics PLC (HZNP): * HORIZON THERAPEUTICS PLC RECEIVES EUROPEAN COMMISSION APPROVAL OF UPLIZNA® FOR THE TREATMENT OF ADULTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER. * HORIZON THERAPEUTICS (HZNP) - EC APPROVAL SUPPORTED BY RESULTS FROM N-MOMEMTUM, SHOWED 87.6% OF AQP4-IGG+ NMOSD PATIENTS ON UPLIZNA WERE ATTACK FREE FOR 28 WEEKS Source text for Eikon: Further company coverage:

-- NMOSD is a devastating autoimmune disease of severe and recurrent central nervous system attacks which can result in blindness, paralysis and death -- -- UPLIZNA is indicated as monotherapy for treatment of adult patients with NMOSD who are anti-aquaporin-4 immunoglobulin G seropositive, which represents 80% of NMOSD patients -- -- EC approval was supported by results from N-MOmemtum, the la...